Skip to main content

PURE BIOSCIENCE, INC.

corporate_fare Company Profile

PURE BIOSCIENCE, INC.

PURE·OTC·Consumer Defensive·CIK 0001006028

The company develops and sells specialized antimicrobial products to address health and environmental issues related to pathogen and hygiene control. Its technology platform uses patented stabilized ionic silver, with initial products containing Silver Dihydrogen Citrate (SDC). SDC is a broad-spectrum, non-toxic antimicrobial agent available in liquid form and various concentrations, known for its effectiveness, low toxicity, non-causticity, and resistance to bacterial development. The company's SDC-based disinfecting and sanitizing products are registered with the United States Environmental Protection Agency (EPA), the United States Food and Drug Administration (FDA), and Health Canada. Beyond manufacturing and distributing these products, the company also supplies SDC-based formulations as raw material ingredients for personal care products. Key offerings include PURE® Hard Surface, a food contact surface sanitizer and disinfectant for restaurant chains, food processors, and transportation companies, and PURE Control®, a direct food contact processing aid. The company sells products directly to end-use customers and through third-party distributors across various industries. SDC is an electrolytically generated source of stabilized ionic silver, which is colorless, odorless, tasteless, and non-caustic. The company produces and markets pre-formulated, ready-to-use products, as well as SDC concentrate for use as an additive or raw material. SDC is a stabilized silver ion complex with a shelf life of several years.

PURE BIOSCIENCE, INC. (OTC:PURE) is a publicly traded company in the Consumer Defensive sector. Wiseek monitors PURE SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • PURE Bioscience Secures $1.0M in Dilutive Private Placement at Discounted Price
  • PURE Bioscience Secures $1.0M Private Placement, Directors Invest Heavily Amidst Going Concern Warning
  • PURE Bioscience Faces Substantial Going Concern Doubts, Relies on Related Party Convertible Debt Despite Sales Growth
  • PURE Bioscience Reports Q2 Revenue Growth Amid Worsening Financial Deficiency
  • Stockholders Approve Significant Increase in Authorized Shares, Enabling Future Dilution

Financial Snapshot

Fiscal year ended July 31, 2025
Revenue
$2.2M
Net Income
-$2.4M
Diluted EPS
-$0.02
Op. Cash Flow
-$2.02M
Gross Profit
$1.3M
Operating Income
-$2.27M
Cash & Equivalents
$334K
Debt / Equity
0.00×
Net Margin
-109.1%
Shares Outstanding
111.89M sh
Source: 10-K · filed 2025-10-29 · accession 0001493152-25-020065
Browse all tickers starting with P →
$0.0655
52-week range · as of 2026-05-05 $0.0386 – $0.2136
Market cap
$8.52M
Volume
22.9K (0.9× avg)
3-mo avg 26.2K
Live data · 2026-06-14 03:52 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PURE - Latest Insights

PURE
May 05, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.067
Real-time Price: $0.0655 info
Change: -$0.0015 (-2%) info
Market Cap: $8.516M info
PURE
May 05, 2026, 5:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.067
Real-time Price: $0.0655 info
Change: -$0.0015 (-2%) info
Market Cap: $8.516M info
PURE
Mar 16, 2026, 9:29 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.080
Real-time Price: $0.0655 info
Change: -$0.0145 (-18%) info
Market Cap: $8.516M info
PURE
Mar 16, 2026, 9:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.080
Real-time Price: $0.0655 info
Change: -$0.0145 (-18%) info
Market Cap: $8.516M info
PURE
Feb 20, 2026, 4:49 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.05672
Real-time Price: $0.0655 info
Change: +$0.00878 (+15%) info
Market Cap: $8.516M info